ALX Oncology (NASDAQ:ALXO) Stock Price Expected to Rise, Piper Sandler Analyst Says

ALX Oncology (NASDAQ:ALXO) had its price target hoisted by stock analysts at Piper Sandler from $8.00 to $9.00 in a research note issued on Thursday,Benzinga reports. The firm currently has an “overweight” rating on the stock.

ALXO has been the topic of a number of other reports. UBS Group decreased their price objective on shares of ALX Oncology from $4.00 to $2.20 and set a “buy” rating on the stock in a research note on Monday, January 27th. Jefferies Financial Group upgraded shares of ALX Oncology from a “hold” rating to a “buy” rating and raised their target price for the company from $2.00 to $3.00 in a research report on Thursday. Cantor Fitzgerald restated an “overweight” rating on shares of ALX Oncology in a research report on Friday, January 24th. Finally, HC Wainwright cut their target price on shares of ALX Oncology from $25.00 to $5.00 and set a “buy” rating on the stock in a research report on Friday, January 24th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $4.14.

ALX Oncology Stock Performance

Shares of NASDAQ:ALXO opened at $1.06 on Thursday. The company’s 50 day simple moving average is $1.39 and its 200 day simple moving average is $1.62. The stock has a market capitalization of $55.91 million, a price-to-earnings ratio of -0.36 and a beta of 1.01. The company has a debt-to-equity ratio of 0.07, a current ratio of 4.82 and a quick ratio of 4.82. ALX Oncology has a 1 year low of $0.95 and a 1 year high of $17.83.

Hedge Funds Weigh In On ALX Oncology

Hedge funds have recently bought and sold shares of the company. JSF Financial LLC bought a new position in ALX Oncology during the fourth quarter worth $29,000. GSA Capital Partners LLP bought a new position in ALX Oncology during the third quarter worth $88,000. Sei Investments Co. bought a new position in ALX Oncology during the fourth quarter worth $102,000. Barclays PLC raised its stake in ALX Oncology by 243.6% during the third quarter. Barclays PLC now owns 59,502 shares of the company’s stock worth $107,000 after buying an additional 42,185 shares during the last quarter. Finally, Bridgeway Capital Management LLC bought a new position in ALX Oncology during the fourth quarter worth $125,000. Institutional investors own 97.97% of the company’s stock.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.